Health Data Research UK Selects MMS as Partner for International COVID-19 Data Alliance
MMS Holdings Inc. has been selected by Health Data Research UK as a partner to support the International COVID-19 Data Alliance (ICODA) initiative. MMS was selected from a pool of the world’s clinical research organizations to provide data engineering services to support a globally coordinated, health data-led research response to tackle the COVID-19 pandemic.
ICODA is an open and inclusive global collaboration of life science, philanthropic and research organizations that have come together to harness the power of health data to respond to the COVID-19 pandemic. Uniting data from a broad set of contributors will enable discoveries that will help treat and prevent COVID-19 and coordinate effective data responses to health challenges of the future.
During the pilot phase of the project, MMS will provide flexible service levels based on the capability of each contributor to transform their data to ICODA standards. The MMS biometrics and data science team will provide simple guidance to the full range of data services and data mapping as needed.
After the pilot completes, MMS data scientists will use learnings to develop tools to further enable contributors such as open-source code and training that academic researchers can use to transform their own data. Additionally, later phases of the engagement may include data mapping and incorporation of real-world health data.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025